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Ventricular Function
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Enrique Lara-Pezzi, PHDa,c,f

ABSTRACT
BACKGROUND In response to pressure overload, the heart develops ventricular hypertrophy that progressively decompensates and leads to heart failure. This pathological hypertrophy is mediated, among others, by the phosphatase
calcineurin and is characterized by metabolic changes that impair energy production by mitochondria.
OBJECTIVES The authors aimed to determine the role of the calcineurin splicing variant CnAb1 in the context of cardiac
hypertrophy and its mechanism of action.
METHODS Transgenic mice overexpressing CnAb1 speciﬁcally in cardiomyocytes and mice lacking the unique C-terminal
domain in CnAb1 (CnAb1Di12 mice) were used. Pressure overload hypertrophy was induced by transaortic constriction.
Cardiac function was measured by echocardiography. Mice were characterized using various molecular analyses.
RESULTS In contrast to other calcineurin isoforms, the authors show here that cardiac-speciﬁc overexpression of CnAb1
in transgenic mice reduces cardiac hypertrophy and improves cardiac function. This effect is mediated by activation of
serine and one-carbon metabolism, and the production of antioxidant mediators that prevent mitochondrial protein
oxidation and preserve ATP production. The induction of enzymes involved in this metabolic pathway by CnAb1 is
dependent on mTOR activity. Inhibition of serine and one-carbon metabolism blocks the beneﬁcial effects of CnAb1.
CnAb1Di12 mice show increased cardiac hypertrophy and declined contractility.
CONCLUSIONS The metabolic reprogramming induced by CnAb1 redeﬁnes the role of calcineurin in the
heart and shows for the ﬁrst time that activation of the serine and one-carbon pathway has beneﬁcial effects on
cardiac hypertrophy and function, paving the way for new therapeutic approaches. (J Am Coll Cardiol 2018;71:654–67)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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METHODS
Full Methods can be found in the Online Appendix.
MICE.

aMHC-CnAb 1 mice express the human CnAb1

isoform in a cardiomyocyte-restricted manner under
the control of the alpha myosin heavy chain ( a MHC)
promoter (4). CnAb 1Di12 mice were generated by deleting intron 12-13 in the gene that encodes CnA b
(Ppp3cb), which encodes the unique C-terminal
domain in CnAb1. Only adult male mice were used in

dex (LVMi) and thinner posterior wall and interventricular septum in CnA b1-overexpressing mice after
TAC compared with WT mice (Figures 1B–1D). In
agreement with the echocardiography results, transgenic mice showed a more limited increase in cardiomyocyte size (Figure 1E). Importantly, whereas
contractility declined in WT mice 21 days after TAC, it
was preserved in CnAb 1-overexpressing mice, as
shown by improved left ventricular ejection fraction
(LVEF) (Figure 1F). Transgenic mice also showed a
limited increase in the expression of the HF markers
atrial natriuretic factor (ANF) and brain natriuretic

this study. All procedures were approved by the
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F I G U R E 1 CnA b 1 Overexpression Reduces Cardiac Hypertrophy
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with these results, we also observed reduced expres-

up-regulation of genes associated with extracellular

sion of the ﬁbrosis markers collagen I a 1 (Col1a1) and

matrix, cell adhesion, and ﬁbrosis (Online Tables 1
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together with reduced levels of SMAD2 phosphoryla-

with the mitochondria (Online Tables 3 and 4).

tion, suggesting reduced TGF- b signaling (Online
Figures 1E to 1G).
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of the endogenous NFAT pathway, we ﬁrst quantiﬁed
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(Figures 2A and 2B). To conﬁrm the activation of the
NFAT pathway, we crossed WT and a MHC-CnA b1
mice with a reporter mouse line in which the
expression of luciferase is controlled by NFAT binding sites. A strong NFAT activation was observed in
both WT and transgenic mice in response to pressure
overload,

as

determined

by

luciferase

activity,

without any substantial change between both mouse
types (Figure 2C). These results indicate that CnAb1
overexpression does not interfere with NFAT activation in cardiac hypertrophy.

expression changes in WT mice following TAC (Online
Figure 3), suggesting that endogenous CnAb 1 and the
serine and one-carbon pathway may play a role in the
response to pressure overload.
Although no gene categories changed signiﬁcantly
in transgenic mice after TAC (Online Tables 9 to 12),

aMHC-CnAb 1 mice showed reduced expression of
extracellular–matrix-related genes compared with
WT (Online Tables 13 to 16), which was conﬁrmed by
qRT-PCR (Online Figures 1E and 1F).
We then carried out a quantitative proteomics
analysis of sham WT and transgenic mice, which also
showed a strong increase in proteins involved in the
serine and one-carbon pathway in a MHC-CnA b1 mice
(Online Table 17, Figure 2D), conﬁrming that serine
and one-carbon metabolism was strongly induced in
the heart by CnAb1.
Many of these genes are regulated by the mTOR
signaling pathway through the transcription factor
activating transcription factor 4 (ATF4) (4,10). To
determine whether this pathway was activated

ONE-CARBON

by CnA b1 in the context of pressure overload, we

METABOLISM. We next analyzed the transcription

analyzed these proteins by Western blot. We observed

proﬁle of WT and transgenic mice using microarrays.

activation of the mTOR/AKT signaling pathway and

Following TAC, WT mice showed a consistent

increased expression of ATF4 in CnA b1-overexpressing

CnA b 1

ACTIVATES

SERINE

AND

F I G U R E 1 Continued

(A) Pressure overload cardiac hypertrophy was induced in wild type (WT) and aMHC-CnAb1 mice by transaortic constriction (TAC) and the heart weight to
body weight ratio was determined 21 days after surgery, compared with sham-operated animals. LVMi (B), LVPWd (C), and IVSd (D) were determined by
echocardiography 21 days after surgery. (E) Cardiomyocyte cross-sectional area was analyzed by immunohistochemistry. (F) LVEF was determined by
echocardiography. Interstitial (G and H) and perivascular (I and J) cardiac ﬁbrosis were analyzed 21 days after TAC using Masson’s trichrome protocol.
Bar indicates 100 mm. Interstitial ﬁbrosis was quantiﬁed as the percentage of area in each picture that is stained as collagen. Perivascular ﬁbrosis was
calculated as the perivascular collagen area relative to the vessel area. At least 2 pictures per mouse were analyzed. Values represent average  SEM.
**p < 0.01, ***p < 0.005 TAC versus sham for each mouse line; †p < 0.05, ††p < 0.01, †††p < 0.005 WT versus transgenic mice; 2-way analysis
of variance plus Bonferroni post-test. n ¼ 12 to 18. CSA ¼ cross-sectional area; HW/BW ¼ heart weight to body weight ratio; IVSd ¼ interventricular
septum thickness in diastole; LVEF ¼ left ventricular ejection fraction; LVMi ¼ left ventricular mass index; LVPWd ¼ left ventricular posterior wall
thickness in diastole.
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F I G U R E 2 CnA b1 Activates the Serine and One-Carbon Metabolic Pathway Without Interfering With NFAT-Mediated Transcription
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Expression of the Rcan1.4 (A) and Rcan1.1 (B) mRNA was analyzed by qRT-PCR 21 days after TAC. (C) WT and aMHC-CnAb1 mice were crossed with reporter mice in
which luciferase expression is controlled by an NFAT binding site multimer. Luciferase activity normalized to total protein content was analyzed in heart extracts
21 days post-TAC. (D) Summary of genes involved in the serine and one-carbon pathway. Components induced in aMHC-CnAb1 mice are indicated by a blue ﬁll (mRNA,
metabolites) or purple border (protein). Expression of Phgdh (E), Psat1 (F), Shmt2 (G), Mthfd2 (H), and Aldh1l2 (I) was quantiﬁed as in (A). Values express average 
SEM. *p < 0.05, **p < 0.01 TAC versus sham for each mouse line; †p < 0.05, ††p < 0.01, †††p < 0.005 WT versus transgenic mice; 2-way analysis of variance plus
Bonferroni post-test. n ¼ 10 to 15 (A, B, and E–I); n ¼ 5 to 12 (C). 3PG ¼ 3-phosphoglycerate; 3P-Ser ¼ 3-phosphoserine; Gly ¼ glycine; NAD(P) ¼ nicotinamide adenine
dinucleotide phosphate; NAD(P)H ¼ nicotinamide adenine dinucleotide phosphate (reduced form); NFAT ¼ nuclear factor of activated T cells; qRT-PCR ¼ quantitative
reverse-transcription real-time polymerase chain reaction; Ser ¼ serine; THF ¼ tetrahydrofolate; other abbreviations as in Figure 1.
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F I G U R E 3 mTOR Mediates the Activation of the Serine One-Carbon Pathway by CnA b 1
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(A) Phosphorylation and/or expression of mTOR, Akt, and ATF4 was analyzed by Western blot in myocardial samples from the indicated mice
21 days after surgery. (B to D) WT and aMHC-CnAb1 uninjured mice were treated with rapamycin for 5 days, and the expression of Phgdh,
Psat1, and Mthfd2 was analyzed in myocardial samples. *p < 0.05, ***p < 0.005 aMHC-CnAb1 versus WT; ††p < 0.01, †††p < 0.005
rapamycin versus vehicle; 2-way analysis of variance plus Bonferroni post-test. n ¼ 5. ATF4 ¼ activating transcription factor 4;
mTOR ¼ mechanistic target of rapamycin; other abbreviations as in Figure 1.

CnAb1-overexpressing

mice (Figure 3A), consistent with our previous results

in

(3,4). To investigate whether mTOR mediates the

Figure 4A). Using Metabolomic Pathway Analysis, we

induction of the serine and one-carbon pathway by

found a strong enrichment of metabolites related to

CnAb 1, we treated uninjured WT and transgenic mice

glutathione, amino acid, and nucleotide metabolic

with the mTOR inhibitor rapamycin, and we analyzed

pathways (Online Figure 4B).

the mice 5 days later. As shown in Figures 3B to 3D,

WT

and

mice

(Online

To explore these changes more in depth, we

mTOR inhibition partially abolished the induction of

analyzed

Phgdh, Psat1, and Mthfd2 in aMHC-CnA b 1 mice,

belonging to the affected pathways. We found a

the

amount

of

different

metabolites

indicating that CnA b 1 activates the serine and one-

strong signiﬁcant induction of glutathione, mainly

carbon pathway through mTOR signaling.

reduced glutathione (GSH), and its precursor metab-

CnA b 1 OVEREXPRESSION CHANGES THE HEART’S

olites (Online Figures 4C and 5, Online Table 18). This

METABOLOME. Phdgh-derived serine synthesis and

was accompanied by a signiﬁcant induction of

the one-carbon cycle supply metabolites for the pro-

methionine metabolites (Online Figure 4D). In addi-

duction of antioxidant mediators such as glutathione

tion, a MHC-CnAb1 mice showed a signiﬁcant increase

(11,12). A thorough metabolomic analysis in uninjured

of several metabolites associated with polyamine

WT and a MHC-CnA b1 mice detected a total of

metabolism and the urea cycle, mainly related to the

462 different metabolites in myocardial samples

degradation of arginine to ornithine, putrescine, and

from both mouse types, with 133 of them being up-

spermidine (Online Figure 4E, Online Table 18). We

regulated in transgenic mice and 65 metabolites

also found that several metabolites related to purine
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and

(Online

Table

18).
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principal
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metabolism
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component analysis showed strong separation of

leading to a strong induction of the potent antioxi-

the samples, suggesting a different metabolic proﬁle

dant urate (Online Table 18). These changes were
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F I G U R E 4 CnA b1 Reduces the Oxidative Damage After Pressure Overload and Improves ATP Synthesis
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Reduced (A) and total (B) glutathione, and ATP generation driven by glutamate þ malate (C) or by succinate (D) were quantiﬁed in whole myocardium from WT and

aMHC-CnAb1 mice 21 days after TAC or sham surgery. *p < 0.05, **p < 0.01 versus sham; ††p < 0.01 WT versus transgenic mice; 2-way analysis of variance plus
Bonferroni post-test. n ¼ 9 to 15 (A and B), n ¼ 8 to 14 (C and D). (E and F) Quantitative redox proteomics analysis using the GELSILOX technique. Shown are the
cumulative distributions of the standardized log2 ratios of abundances (Zqp) of peptides containing oxidized cysteine residues in the conditions that are compared. The
peptides belong to either mitochondrial proteins (E) or proteins associated with the Krebs cycle or muscle contraction (F). The null hypothesis distribution, which
reﬂects identical peptide abundances in the 2 conditions, is represented by a gray line. The blue lines show the relative abundance of peptides from WT mice after TAC in
relation to those from WT mice after sham surgery, whereas the orange lines represent the peptides from aMHC-CnAb1 mice after TAC in relation to WT mice after TAC.
Positive values of Zqp indicate increase in relative peptide abundance. ATP ¼ adenosine triphosphate; GSH ¼ reduced glutathione; other abbreviations as in Figure 1.

paralleled by a strong increase in another antioxi-

complex

dant, ascorbate (Online Figure 4F). Together, these

Figure 6C). Analysis of the activity of the different

components

by

Western

blot

(Online

changes indicated that CnA b 1 activates several

mitochondrial complexes showed a signiﬁcant in-

metabolic pathways with antioxidant activity.

crease in the activity of complexes IþIII and IIþIII in

MITOCHONDRIAL COMPLEXES SHOW INCREASED
ACTIVITY

IN

CnA b 1-OVEREXPRESSING

aMHC-CnAb1 mice (Online Figure 6D). In addition, we

MICE. To

observed increased citrate synthase activity in trans-

determine whether the changes in the metabolic

genic mice, in agreement with the increase in citrate

proﬁle observed in transgenic mice would impact

detected by mass spectrometry (Online Table 18) and

mitochondrial number or activity, we analyzed

with the slight increase in mtDNA copy number

different parameters in uninjured mice. We ﬁrst

(mitochondrial mass). These changes in the activity of

quantiﬁed mitochondrial DNA and found no signiﬁ-

mitochondrial complexes, however, had no effect on

cant differences between WT and a MHC-CnA b1 mice,

the production of ATP by isolated mitochondria,

although a small increase was observed in transgenic

neither driven by glutamate and malate nor by succi-

mice (Online Figure 6A). Analysis of mitochondrial

nate (Online Figure 6E).

complexes and supercomplexes in isolated mito-

CnAb1 REDUCES PROTEIN OXIDATION AND IMPROVES ATP

chondria revealed no differences between both mouse

SYNTHESIS FOLLOWING PRESSURE OVERLOAD. We next

types (Online Figure 6B). Similarly, we observed no

investigated whether the changes observed in unin-

obvious differences in the expression of individual

jured mice were reproduced in the hypertrophic

Padrón-Barthe et al.

JACC VOL. 71, NO. 6, 2018

CnAb1 Improves Function Through 1C Metabolism

FEBRUARY 13, 2018:654–67

F I G U R E 5 Inhibition of Serine Synthesis From Glucose Abolishes the Beneﬁcial Effects of CnA b 1
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Mice underwent TAC or sham surgery and LVMi (A) and LVEF (B) were analyzed by echocardiography 21 days later. Where indicated, mice
were treated with the PHGDH inhibitor NCT-503 for 21 days. ATP synthesis from glutamate and malate (C) or succinate (D) was analyzed in all
mice. Note that the control (untreated) animals for these analyses are those shown in Figure 1 (for A and B) and Figure 6 (for C and D), and are
repeated here for comparative purposes. *p < 0.05, **p < 0.01, ***p < 0.005 TAC versus sham for each mouse line; ††p < 0.01, †††p <
0.005 WT versus transgenic mice; ‡p < 0.05, TAC NCT-503–treated mice versus TAC untreated mice; 2-way analysis of variance plus
Bonferroni post-test. n ¼ 6 to 18 (A and B), n ¼ 6 to 14 (C and D). Abbreviations as in Figures 1 and 4.

heart. Using an enzymatic assay, we found an in-

the same peptide populations in comparison to WT-

crease in GSH in a MHC-CnA b1 mice compared with

TAC mice (Figures 4E and 4F), suggesting that the

WT, which was more evident 21 days after TAC

antioxidant response elicited by CnAb1 prevents

(Figure 4A). We also found an increase in total gluta-

mitochondrial and sarcomere protein oxidation, and

thione in transgenic mice, albeit at much lower levels

hence

(Figure 4B). We observed a strong reduction in the

contraction.

production of ATP by mitochondria isolated from WT

ACTIVATION OF THE SERINE AND ONE-CARBON

mice after TAC, both driven by glutamate and malate

PATHWAY IS NECESSARY FOR THE INDUCTION OF

(Figure 4C) and by succinate (Figure 4D). By contrast,

ATP AND REDUCTION OF CARDIAC HYPERTROPHY

mitochondria from a MHC-CnA b1 mice showed pre-

BY CnA b 1. To determine the functional relevance of

served ATP production level after TAC, signiﬁcantly

the activation of serine one-carbon metabolism by

improves

ATP

production

and

cardiac

higher than that of WT mice (Figures 4C and 4D). Us-

CnAb1, we treated WT and transgenic mice for 21 days

ing the GELSILOX technique (13), we observed an

after TAC surgery with the PHGDH inhibitor NCT-503,

increase in oxidized peptides from mitochondrial

which blocks the synthesis of serine from glucose and

proteins, particularly those related to the Krebs cycle,

its contribution to the one-carbon pathway (14).

and from muscle contraction proteins in WT mice

Treatment of a MHC-CnA b1 mice with NCT-503 resul-

21 days after TAC (WT-TAC mice) (Figures 4E and 4F,

ted in increased LVMi and reduced LVEF compared

Online Tables 19 to 21). Interestingly, a MHC-CnA b1

with untreated transgenic mice (Figures 5A and 5B).

mice subjected to TAC showed reduced oxidation of

Furthermore, NCT-503 prevented the improved ATP
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F I G U R E 6 Glutathione Is Necessary for the Functional Improvement Induced by CnA b 1 After Pressure Overload
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(A and B) WT and transgenic mice underwent sham or TAC surgery and were treated with L-buthionine-sulfoximine (BSO) for 21 days. Reduced (A) and total (B)
glutathione, and ATP synthesis from glutamate and malate (C) or succinate (D) were measured in myocardial samples. Values are expressed as percentage  SEM,
referred to untreated WT sham mice (dashed line). LVMi (E) and LVEF (F) were determined by echocardiography in BSO-treated and untreated (control) mice 21 days
after surgery. Note that the control (untreated) animals for these comparisons are those shown in Figure 1, and are repeated here for comparative purposes. *p < 0.05,
**p < 0.01, ***p < 0.005, TAC versus sham for each mouse line; †p < 0.05, †††p < 0.005 aMHC-CnAb1 versus WT; ‡p < 0.05 BSO versus control; 2-way analysis of
variance plus Bonferroni post-test. n ¼ 5 to 9 (A and B), n ¼ 3 to 9 (C and D), n ¼ 5 to 18 (E and F). Abbreviations as in Figures 1 and 4.

synthesis induced by CnA b1, both from glutamate and

mice (Figures 6C and 6D), compared with untreated

malate, and from succinate. Transgenic mice showed

sham WT mice. This was accompanied by a slight

similar ATP levels to those of WT mice and signiﬁ-

reduction in ventricular wall thickness, although

cantly reduced compared with untreated aMHC-

cardiac hypertrophy proceeded normally in response

CnA b1 mice (Figures 5C and 5D). These data indicate

to TAC (Figure 6E). Importantly, in the presence of

that the serine and one-carbon pathway is necessary

BSO, WT and a MHC-CnA b1 mice showed a similar

for the beneﬁcial effects of CnAb1 on the heart.
GLUTATHIONE MEDIATES THE IMPROVED RESPONSE TO
PRESSURE OVERLOAD IN aMHC-CnAb1 MICE. To ﬁnd out

increase in LVMi (Figure 6E). BSO treatment also
resulted in reduced LVEF following TAC in CnAb1overexpressing mice, whereas no decline in cardiac

whether the increase in reduced glutathione was also

contractility was observed in WT mice (Figure 6F).

responsible for the improvement in ATP production

Together, these results suggest that the induction of

and cardiac function observed in a MHC-CnA b1 mice

GSH by CnAb 1 is necessary for the functional and

after TAC, we treated both WT and CnA b1 over-

structural improvement triggered by this calcineurin

expressing mice with BSO, which decreases gluta-

isoform and that in the absence of glutathione, the

thione synthesis by inhibiting g -glutamylcysteine

increased substrate ﬂux through the oxidative phos-

synthetase (15). Administration of BSO resulted in a

phorylation chain induced by CnAb1 may have dele-

strong reduction in both GSH and total glutathione in

terious effects on cardiac function decompensation

both WT and transgenic mice, and prevented the in-

following pressure overload.

crease in GSH induced by CnA b 1 (Figures 6A and 6B).

MICE LACKING CnAb1 DEVELOP CARDIAC HYPERTROPHY.

The levels of untreated sham-operated WT mice are

To determine the role of endogenous CnA b1, we

showed for reference. Inhibition of glutathione syn-

developed knockout mice lacking intron 12-13 in the

thesis caused a strong decrease in ATP synthesis in all

CnAb gene (CnAb1 Di12 mice), which codes for the
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F I G U R E 7 Mice Lacking the C-Terminal Domain of CnA b 1 Show Increased Cardiac Hypertrophy
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(A) Schematic of the strategy used to generate the CnAbDi12 mice. (B and C) CnAb1 and CnAb2 expression was analyzed by qRT-PCR in WT and CnAbDi12 mice. n ¼ 19 to
25. The corrected (D) and indexed (E) left ventricular (LV) mass were analyzed by echocardiography at 2, 8, and 15 months of age. n ¼ 6 to 18. (F) Cardiomyocyte
cross-sectional area was analyzed by histological methods. n ¼ 5 to 14. (G) Systolic and diastolic blood pressure were measured in 15-month-old WT and CnAbDi12 mice.
n ¼ 6 to 11. (H) LVEF was analyzed by echocardiography at 2, 8, and 15 months. n ¼ 7 to 18. ATP synthesis from glutamate and malate (I) or from succinate (J) was
quantiﬁed in WT and CnAbDi12 mice. n ¼ 6 to 10. (K and L) BNP and Rcan1.4 mRNA expression was quantiﬁed by qRT-PCR. n ¼ 19 to 25. (M) Western blot analysis of

NFATc3 in WT and CnAb1Di12 mice (n ¼ 4) (smaller bands indicate activation by dephosphorylation). Phosphorylated (active) and total forms of kinases in the p38 and

JNK pathways were also analyzed. **p < 0.01, ***p < 0.005, 8 and 15 months versus 2 months for each mouse line; †p < 0.05, ††p < 0.01, WT versus CnAbDi12 mice;
2-way analysis of variance plus Bonferroni post-test. Abbreviations as in Figures 1 and 4.
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F I G U R E 8 CnA b D i12 Mice Develop Increased Hypertrophy Following Pressure Overload
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Left ventricular (LV) mass corrected (A), LVMi (B), and LVEF (C) were analyzed by echocardiography 21 days after TAC in WT and CnAbDi12 mice. n ¼ 7 to 8.

Expression of ANF (D), Phgdh (E), and Psat1 (F) was analyzed by WT and CnAbDi12 mice by qRT-PCR 21 days after surgery. n ¼ 5 to 7. *p < 0.05,

**p < 0.01, ***p < 0.005 TAC versus Sham for each mouse line; †p < 0.05, ††p < 0.01, †††p < 0.005, WT versus CnAbDi12 mice; 2-way analysis of variance

plus Bonferroni post-test. ANF ¼ atrial natriuretic factor; other abbreviations as in Figure 1.

unique C-terminal domain in CnA b1 (Figure 7A).

contractile capacity was paralleled by a decreased

Although these mice express no CnA b 1, expression

ability to produce ATP, both from glutamate and

of

the

traditional

isoform

CnA b2

unaltered

malate and from succinate (Figures 7I and 7J).

(Figures 7B and 7C). CnA b1Di12 mice are viable and

Furthermore, we found increased expression of BNP

fertile, and are born at the expected Mendelian ratio.

and

However, we observed a signiﬁcant increase in car-

CnAb1 Di12 mice (Figures 7K and 7L). Increased acti-

diac hypertrophy with age. Echocardiographic anal-

vation of NFATc3 was conﬁrmed by Western blot

ysis showed increased left ventricular mass in

(Figure 7M), and it was likely due to the inhibition of

CnA b1D i12 mice at 15 months of age and increased

the MAPKs p38 and JNK, which rephosphorylate and

cardiomyocyte area (Figures 7D to 7F). No changes

inhibit NFATc. Inhibition of JNK and p38, their up-

were observed in blood pressure (Figure 7G), sug-

stream kinases MKK4 and MKK3/6, or their upstream

gesting

the

MKK kinase ASK1 has been reported to induce car-

consequence of systemic hypertension. Cardiac hy-

diac hypertrophy through NFAT activation (16–18).

pertrophy was accompanied by a decline in LVEF in

We found decreased phosphorylation (indicating

CnAb 1-deﬁcient mice (Figure 7H). This reduced

decreased activation) of the MKK4/JNK and the

that

cardiac

hypertrophy

is

was

not

the

NFAT-regulated

Rcan1.4

isoform

in
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C ENTR AL I LL U STRA T I O N Summary of CnA b 1 Signaling in the Cardiomyocyte and
its Effect on Cardiac Function

Padrón-Barthe, L. et al. J Am Coll Cardiol. 2018;71(6):654–67.
CnAb1 activates mTOR and ATF4 to induce serine and one-carbon metabolism and promote the production of GSH, among other mediators.
Increased GSH results in reduced mitochondrial protein oxidation and increased ATP production, which improves cardiac function and
remodeling after pressure overload. ATF4 ¼ activating transcription factor 4; ATP ¼ adenosine triphosphate; GbL ¼ G protein beta subunit-like;
GSH ¼ reduced glutathione; mTOR ¼ mechanistic target of rapamycin.

MKK3/6/p38 pathways and a mild inhibition of ASK1,
which regulates both pathways, in CnAb 1Di12 mice

DISCUSSION

(Figure 7M). These results suggest that the increased

Calcineurin activation plays a central role in the

hypertrophy observed in old CnA b1Di12 mice is the

development of maladaptive cardiac hypertrophy.

result of JNK and p38 inhibition and subsequent

In contrast with this view, we show here that

NFATc activation. We next studied the response of

overexpression of the alternative splicing CnAb

CnAb1D i12 mice to pressure overload. Three weeks

variant CnA b1 reduces cardiac hypertrophy and im-

after TAC, CnA b1-deﬁcient mice showed increased

proves energy production, whereas deletion of its

cardiac hypertrophy, indicated by the larger left

C-terminal unique domain results in spontaneous

ventricular mass (Figures 8A and 8B). LVEF, howev-

cardiac hypertrophy and decreased ATP synthesis,

er, was higher in CnAb 1Di12 than in control mice

suggesting that the metabolic effects of calcineurin

(Figure 8C), suggesting that cardiac hypertrophy had

on the heart may be isoform-speciﬁc.

not yet decompensated. CnAb 1Di12 mice showed

Interestingly, we found that CnAb1 overexpression

higher ANF expression after TAC surgery, in agree-

activates serine and one-carbon metabolism in an

ment with the increased hypertrophy, and reduced

mTOR-dependent manner. This pathway is a major

expression of genes involved in serine and one-

source of NADH and NADPH, and supplies metabo-

carbon metabolism, including Phgdh, Psat1, Shmt2,

lites to major metabolic pathways in the cells,

and Aldh1l2 (Figures 8D to 8I). These results suggest

including nucleotide biosynthesis, amino acid ho-

that CnA b1 is necessary for normal energy homeo-

meostasis, methylation reactions, and antioxidant

stasis in the heart and that the disturbance of this

defense (12,19). The serine and one-carbon pathway

pathway exacerbates cardiac hypertrophy.

has recently gained strong attention in the cancer
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research ﬁeld (12). Many tumor cells are dependent

which was likely the direct result of hypertrophy it-

on serine and increase Phgdh and Psat1 expression to

self, because cardiac function had not yet decom-

increase serine availability, which provides these

pensated in these animals by 21 days. CnAb Di12 mice

cells with a metabolic advantage (20). Serine and one-

showed decreased expression of enzymes involved in

carbon metabolism is also triggered by mitochondrial

the serine synthesis pathway, after either TAC or

dysfunction (21,22). Its role in the heart, however, is

sham surgery, suggesting that activation of this
pathway by CnA b1 is necessary for the maintenance

virtually unknown.
Here, we show for the ﬁrst time to our knowledge
that serine and one-carbon metabolism has a beneﬁcial effect on the heart, necessary for the improved
ATP synthesis and cardiac function induced by

of energy balance and cardiac homeostasis.
STUDY LIMITATIONS. This study was performed in

mice. Although we show evidence of the beneﬁcial
effects of CnAb1 overexpression and activation of the

CnAb 1. Activation of this pathway leads to the

serine and one-carbon pathway in the mouse heart,

generation of antioxidant metabolites that may be

translation of results obtained in mice to humans is

protective against reactive oxygen species, espe-

not always straightforward.

cially GSH. GSH production is reduced following
pressure overload, and this reduction has a causal
effect on the development of cardiac hypertrophy,
ﬁbrosis, and remodeling that leads to a decline in

CONCLUSIONS
Our results demonstrate that CnA b1 has an opposite

cardiac function after TAC (23). Consistent with this

effect on the heart to that of other calcineurin iso-

beneﬁcial effect of GSH on the hypertrophic heart,

forms. We unveil the activation of the serine and one-

we observed that inhibition of glutathione synthesis

carbon metabolic pathway by CnA b1 and show its

prevents the functional improvement induced by

beneﬁcial role in the heart for the ﬁrst time. These

CnAb 1.

changes in our understanding of cell signaling and

We found that NFAT is equally activated in WT and

metabolism during pressure overload hypertrophy

aMHC-CnAb 1 mice after TAC, suggesting that CnAb 1 is

may lead to the development of novel therapeutic

not acting as an indirect inhibitor of NFAT. Instead,

avenues based on the modulation of serine and one-

CnAb 1 activates the mechanistic target of rapamycin

carbon metabolism.

(mTOR)/Akt pathway and the transcription factor
ATF4. We have previously reported that CnAb1 acti-

ADDRESS

vates this pathway by direct interaction of its C-ter-

Lara-Pezzi, Myocardial Pathophysiology Area, Centro

FOR

minal domain with the mTORC2 complex and that it

Nacional

induces ATF4 in an mTOR-dependent manner (4,6).

Carlos III (CNIC), Melchor Fernández Almagro 3,

Serine and one-carbon genes are known to be regu-

28029 Madrid, Spain. E-mail: elara@cnic.es.

de
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lated by ATF4 upon activation of mTOR (10,11,21).
These data, together with the inhibition of these
genes by rapamycin in our transgenic mice, suggest
that activation of the mTOR/ATF4 pathway by CnAb1
induces metabolic changes that allow the cardiomyocyte to obtain energy and NADH/NADPH
through

the

serine

and

one-carbon

pathway,

decreasing mitochondrial protein oxidation and preserving ATP production after pressure overload
(Central Illustration).
We also report here the ﬁrst description of mice
lacking CnA b1 following the deletion of CnAb intron
12-13. CnAb

D i12

mice are viable and fertile, and show

no obvious malformation during embryonic development. However, they develop cardiac hypertrophy
at 15 months of age. This is accompanied by a
reduction in ATP production and a decline in cardiac
function. In addition, we show that CnAb

D i12

mice

develop increased cardiac hypertrophy after TAC. We
observed an improvement in LVEF in these mice,

PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
CnAb1 overexpression in cardiomyocytes reduces left
ventricular hypertrophy and remodeling, and improves systolic function following pressure overload.
CnAb1 promotes metabolic reprogramming of the
myocardium, activating the serine one-carbon
pathway, and generation of several antioxidant metabolites. These metabolic changes are necessary to
preserve ATP synthesis and improve cardiac function
in CnAb1-overexpressing mice.
TRANSLATIONAL OUTLOOK: Further research is
needed to explore the therapeutic potential of serine
one-carbon pathway activation for patients with heart
failure.
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